Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I take my passport everywhere I travel… DEBUNKED
Everyone knows who I am little_voice… and, everyone that knows me is laughing at the thought of your suggestion…
With that said, I’m confident everyone understands your motives.
I really don’t follow your logic, but good try
The last time I checked, Chris wasn’t in charge of that department
There is no evidence that can prove what you’re suggesting. Assumptions don’t qualify as evidence.
Right guy! Same person that’s on his Facebook page!!!
Are you talking about Officer Lonsford’s Medal of Valor??? Sounds like a real bad dude if you ask me??
https://investorshub.advfn.com/uimage/uploads/2021/9/28/hjynm3F7BAAEE-C801-4DB9-9E89-639DF04346E1.jpeg
https://investorshub.advfn.com/uimage/uploads/2021/9/28/ak%5BbuAC42A021-7784-479D-88D2-ADAEAA01864C.jpeg
Or, his attending the State of the Union as the personal guest of President Clinton???
Reverse spilt most likely… wonder how those call are doing???
But, but, but you said they were a legitimate law firm
Scooter… this must be legit if you claim the same law firm chasing CYDY is legit…
12:38a ET 9/20/2021 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humanigen, Inc. - HGEN
Mentioned: HGEN
Pomerantz LLP is investigating claims on behalf of investors of Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
https://mma.prnewswire.com/media/1486339/Pomerantz_Logo.jpg
The investigation concerns whether Humanigen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On September 9, 2021, Humanigen issued a press release announcing that "the U.S. FDA has declined its request for emergency use authorization of lenzilumab to treat newly hospitalized COVID-19 patients." Humanigen advised investors that "n its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19." On this news, Humanigen's stock price fell sharply during intraday trading on September 9, 2021.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT:Robert S. WilloughbyPomerantz LLP rswilloughby@pomlaw.com 888-476-6529 ext. 7980
https://c212.net/c/img/favicon.png?sn=DC11935&sd=2021-09-20
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-humanigen-inc---hgen-301380104.html
SOURCE Pomerantz LLP
https://rt.prnewswire.com/rt.gif?NewsItemId=DC11935&Transmission_Id=202109200038PR_NEWS_USPR_____DC11935&DateId=20210920
comtex tracking
COMTEX_393642338/1005/2021-09-20T00:38:09
12:38a ET 9/20/2021 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humanigen, Inc. - HGEN
Mentioned: HGEN
Pomerantz LLP is investigating claims on behalf of investors of Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
https://mma.prnewswire.com/media/1486339/Pomerantz_Logo.jpg
The investigation concerns whether Humanigen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On September 9, 2021, Humanigen issued a press release announcing that "the U.S. FDA has declined its request for emergency use authorization of lenzilumab to treat newly hospitalized COVID-19 patients." Humanigen advised investors that "n its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19." On this news, Humanigen's stock price fell sharply during intraday trading on September 9, 2021.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT:Robert S. WilloughbyPomerantz LLP rswilloughby@pomlaw.com 888-476-6529 ext. 7980
https://c212.net/c/img/favicon.png?sn=DC11935&sd=2021-09-20
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-humanigen-inc---hgen-301380104.html
SOURCE Pomerantz LLP
https://rt.prnewswire.com/rt.gif?NewsItemId=DC11935&Transmission_Id=202109200038PR_NEWS_USPR_____DC11935&DateId=20210920
comtex tracking
COMTEX_393642338/1005/2021-09-20T00:38:09
Thanks for clarifying my “hyperbole”
HGEN changed endpoint and study size (more than once)
HGEN reverse split, crash and burn
HGEN no EUA
HGEN better than CYDY… that my friend is hyperbole
HGEN only changed its endpoint 129 times. Nothing to see here
HGEN effective per your comments, but they have no EUA…
I wonder if Dr. Kelly can get me a deal on a 66 Cobra?
That depends on what your definition of is, is(lol)
I have gone on record as stating I believe CYDY may benefit from new leadership as leronlimab is advanced foreword. But, simply cutting the head off isn’t the answer either! Precision medicine is conducted with a scalpel not a machete IMO.
Nothing is nothing without effective management. See… we can find common ground
I sure hope nothing bad happens
Fortunately we have this forum that remains untainted!
You have repeated what I said already… getting rid of the CEO is the easy part…
There is a BIG difference between the government and a biotech like CYDY IMO… but, I guess everyone here would agree our government is a smooth running machine…
Mom and pop investors (all investors) have an obligation to conduct their own DD. Any legal responses are those made by business card lawyers chasing every ambulance in the country.
Prove that the relationship has resulted in financial gains over a 2-year period!!!
Chris doesn’t hide behind an alias on FB and from what I’ve noticed, over the last year or so, is that he doesn’t comes across as a “promoter” with the posts he makes. It’s true most of his posts are slanted towards pro CYDY/Nader, but I’ve also seen him make posts that were balanced and even suggested people remain open-minded during the initial 13D announcements.
So, is it possible the relationship developed based on the good work Chris had done moderating that board and the financial relationship only developed more recently?
I’ve heard rumors of other boards where moderators are paid or have financial incentives to promote and/or obstruct messages to meet their own nefarious objectives. They have also hidden behind aliases which draws more curiosity of their true motives… all IMO
Prove Chris Lonsford has been getting paid for 2 years!!! Show another filing other than last weeks that includes Mr. Lonsford or move to the next topic!!!
That’s a ludicrous statement IMO!!!
That’s a ludicrous statement IMO!!!
You don’t cut your nose-off despite your face!!! It’s easy to remove the CEO, but an altogether different task to replace and takeover the company once the CEO has been replaced.
No plan is perfect and the armchair QB’s always have the answers after the game has been played… but, if it were up to me, the 13D effort would have been initiated through recruiting a legitimate activist who was unemotional, understood the nuances of the science, had the financial wherewithal, and the willingness to battle through the noise from both sides… I am not concerned with the noise around IncellDX, but I don’t believe that would have even been brought up had an activist been pursuing the board seat. The 13D effort was weakened significantly by the “potential” conflict of interest regardless of the legitimacy of the claim IMO… while noble, having shareholders pull resources together was also unwise IMO…
From there, the activist gains a seat on the board, inserts their influence, and affects change in a productive manner without disrupting the companies day-to-day activities… anyway I look at it, the current alternative will create a disruption IMO…
Some may argue this plan would take too long, but we’ve all probably heard the wisdom given by papa bull when he warned baby bull about rushing down to pasture… With that said, I’m in this for the long-game and have the patience to do things the right way.
The one thing I completely agree with Mr. Rosenbaum on is that Nader deserves a lot of credit for what he’s done to get leronlimab to this stage. However (IMHO), a stronger “like-minded” candidate may be needed to lead the company through its commercial evolution.
As things currently stand, I am supporting CytoDyn management’s proxy slate, but it’s a long time until October 27th…
The fixation on Nader is a distraction to manipulate investors who don’t understand what’s going on behind the scenes IMO!
Would CytoDyn benefit from a different CEO as leronlimab advances? I think yes…
Does the group attempting to oust him now have the vision and capacity to do better than the nominees on CytoDyn proxy submitted yesterday? I am not convinced yet…
Thanks for showing us the truth Scooter!
YOU ARE WRONG
Famous last words
Bankruptcy debunking on a Friday afternoon(-;
Unfortunate truth for biotechs… they need the financial flexibility and it’s significantly better than a reserve split IMO!!!
https://ir.stockpr.com/cytodyn/sec-filings-email/content/0001193125-21-282502/d246474dprec14a.htm
Proposals and Board Recommendations for Voting
PROPOSAL
RECOMMENDATION
PAGE
Proposal 1 – Election of six (6) directors to serve on the Board of Directors until the 2022 annual meeting of stockholders, until their successors are duly elected and qualified or until their earlier death, resignation or removal
“FOR” EACH OF OUR BOARD’S NOMINEES 18
Proposal 2 – Ratification, on an advisory (non-binding) basis, of the selection of Warren Averett, LLC as our independent registered public accounting firm for the fiscal year ending May 31, 2022
FOR 21
Proposal 3 – Approval, on an advisory (non-binding) basis, of our named executive officer compensation
FOR 22
Proposal 4 – Approval of a proposal to amend the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock from 800,000,000 to 1,000,000,000
FOR
The Board recommends that stockholders vote “FOR” each of the Board’s Nominees on the enclosed proxy card.
Nominees and their Qualifications
The following table sets forth information with respect to each person who is nominated for election as a director, including their current principal occupation or employment and age as of September 24, 2021.
18
Table of Contents
The experience, qualifications, attributes and skills of each nominee, including his or her business experience during the past five years, are described below:
Name Age
Principal Occupation
Business Address
Scott A. Kelly, M.D.
51 Chairman of the Board, Chief Medical Officer, Head of Business Development
1111 Main St, Ste 660,
Vancouver, WA 98660
Nader Z. Pourhassan, Ph.D.
58 President and Chief Executive Officer
1111 Main St, Ste 660,
Vancouver, WA 98660
Jordan G. Naydenov
61 Vice President and Treasurer of Milara, Inc.
1111 Main St, Ste 660,
Vancouver, WA 98660
Lishomwa C. Ndhlovu, M.D., Ph.D.
51 Professor of Immunology in Medicine and Neuroscience, Cornell University
413 East 69th St
New York, NY 10021
Harish Seethamraju, M.D.
50 Medical Director, Mount Sinai, Lung Transplantation Program
10 East 102nd Street
New York, NY 10029
Tanya Durkee Urbach
54 Partner in Eagle Bay Advisors 7 World Trade Center, 250 Greenwich St, 46th Floor,
Interesting to read through all of the convincing information supporting the pending “guaranteed” failure of CYDY and Nader Pourhassan…
I only question why it’s necessary to continue with this overwhelming litany of posting about the terrible Nader, the water shot, the certain bankruptcy, etc…
Must be altruism… b/c, I would be on to the next opportunity if I was so certain of these failures!!!
My understanding is Nader didn’t do anything to improve the relationship, but there were issues with the previous individual who led the discussions prior to Nader having the mike…
I’d suggest a solid trial is setup in Brazil and, “if” the results are “fantastic”, “perhaps” it won’t matter and the FDA will “possibly” accept those results for the critical population…
Funny how there’s always something to counter an argument… who knows really???
SEC questioned CYDY filing regarding leronlimab’s safety profile
CYDY responded
SEC had no follow up questions regarding safety profile and the filing was completed
What logical outcome of a completed filing leads you to believe the matter is not closed?
Investigations may or, may not be about the filing… show me the PROOF the investigation relates to this specific filing!!!